CVI Holdings’s BioCryst Pharmaceuticals BCRX Stock Holding History

CVI Holdings’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-148,952	Closed	-$514K	–	40
2019 Q4	$514K	Buy	+148,952	New	+$375K	0.72%	18

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

CVI Holdings's BCRX Position: Q1 2020 in Review

CVI Holdings sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2020, closing a stake of 148,952 shares — an estimated $514K sold.

CVI Holdings first reported a position in BCRX in Q4 2019 and held it in 1 quarter. The position peaked at $514K in Q4 2019. 134 funds tracked by Wall St. Rank hold BCRX as of Q1 2020.

CVI Holdings reported no remaining BioCryst Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
CVI Holdings sold 148,952 BioCryst Pharmaceuticals shares in Q1 2020, an estimated $514K.
CVI Holdings first reported a position in BioCryst Pharmaceuticals in Q4 2019 and held it in 1 quarter.
CVI Holdings's BioCryst Pharmaceuticals position peaked at $514K in Q4 2019.
134 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2020.

Based on CVI Holdings's 13F filing for Q1 2020, filed 15 May 2020.